
Areas of Expertise
Conditions I Treat
- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
My Specialties
- Early drug development
- Clinical trials
- Early-phase clinical trials
Get to Know Me
I am a hematologist-oncologist who specializes in caring for people with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. I am dedicated to providing my patients with the best care tailored to their unique situation. To do this, we work together to develop a personalized treatment plan that takes into account their needs as well as their family’s.
I am also an active clinical researcher who develops new and innovative approaches to treating acute myeloid leukemia (AML).
Read more
I am the principal investigator on a wide variety of clinical trials for people with AML. I am working to develop new therapies — such as small molecule inhibitors — that can more precisely and effectively target AML. My goal as a doctor and researcher is to help people with AML and other blood cancers have the best possible outcomes.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
- Chief, Leukemia Service
- Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies
Conditions I Treat
- Leukemia
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Acute promyelocytic leukemia (APL)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- Myeloproliferative neoplasms (MPN)/Myeloproliferative disorders
- Myelodysplastic syndrome (MDS)
- Hairy cell leukemia (HCL)
- Systemic mastocytosis
- Blood, bone marrow, and hematologic cancers and conditions
My Specialties
- Early drug development
- Clinical trials
- Early-phase clinical trials
- Targeted therapy
Education
- MD, Northwestern University Medical School
Residencies
- Northwestern Memorial Hospital
Fellowships
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

Contact and Location
Dr. Stein sees patients at one location.






Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Stein
- A Phase 1 Study of BH-30236 in People With Acute Myelogenous Leukemia or Higher-Risk Myelodysplastic Syndrome
- A Phase 1 Study of GLB-001 in People With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- A Phase 1 Study of REM-422 in People With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- A Phase 1 Study of SGR-2921 in People With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Read more
- A Phase 1B Study of Gilteritinib Plus Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia
- A Phase 2 Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia
- A Phase I Study of BTX-A51 in People with Recurrent or Persistent Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- A Phase I/II Study of SNDX-5613 in People with Recurrent or Persistent Acute Leukemia
- Access to SNDX-5613 to Treat People with Leukemia
- Clinical Trials Co-Investigated by Dr. Stein
- A Phase 1 Study of Ziftomenib Combinations in People With Acute Myeloid Leukemia
- A Phase 1B Study of DFV890 in People With Myeloid Diseases
- A Phase 2 Study of AG-946 in People with Anemia Due to Myelodysplastic Syndromes
- A Phase 2 Study of Canakinumab in People With Clonal Cytopenia of Unknown Significance

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Stein’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
4.9 235 reviews
- 4.9 Provider's Explanations Easy to Understand
- 4.9 Trusts Provider with Care
- 4.9 Provider Listened Carefully
- 4.9 Likelihood of Recommending Provider
Excellent customer service
Best Dr
Dr Stein is a very caring Doctor who calmed me down and gave me hope about my condition. Very pleased to have him as my Doctor.
I felt the appointment was beautifully handled from start to finish and was, have only the highest recommendation for Dr. Stein and his staff. Thank you. Bye-bye.
At times, there appears to be a shortage of nurses and technicians that can delay certain procedures (e.g., Phlebotomy). However, that being said, the nurses and technicians that are present are top notch.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Eytan M. Stein discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Agios Pharmaceuticals
Professional Services and Activities -
Astellas
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
Auron Therapeutics, Inc.
Equity -
Celgene
Professional Services and Activities -
Genentech
Professional Services and Activities
-
Gilead Sciences, Inc.
Professional Services and Activities -
Jazz Pharmaceuticals
Professional Services and Activities -
Oncolyze Inc.
Equity -
Scaffold Therapeutics, Inc.
Equity -
Servier
Professional Services and Activities -
Treeline Biosciences, Inc.
Equity -
Trio Pharmaceuticals, Inc.
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.